ID   AC-33
AC   CVCL_Z046
DR   JCRB; IFO50155
DR   Wikidata; Q54607870
RX   Patent=US5126259;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2143.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Discontinued: JCRB; IFO50155; true.
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
DI   NCIt; C97074; Hereditary spherocytosis
DI   ORDO; Orphanet_822; Hereditary spherocytosis
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6544 ! WIL2
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 12
//
RX   Patent=US5126259;
RA   Tada H., Toyoda Y., Kakinuma A.;
RT   "Human b lymphoblastoid cell, hybridoma, antibody and production of
RT   antibody.";
RL   Patent number US5126259, 30-Jun-1992.
//